These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35613944)

  • 1. Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation.
    Dunn W; Song X; Koestler D; Grdinovac K; Al-Hihi E; Chen J; Taylor R; Wilson J; Weinman SA
    J Gastroenterol Hepatol; 2022 Sep; 37(9):1815-1821. PubMed ID: 35613944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Detection of Fibrotic Nonalcoholic Fatty Liver Disease in Community-Based Referrals.
    Piao C; Arteaga EJ; Chen S; Guo A; Macdonald ST; Sarkar S
    Metab Syndr Relat Disord; 2023 Nov; 21(9):475-478. PubMed ID: 37756226
    [No Abstract]   [Full Text] [Related]  

  • 3. Predicting Liver-Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests.
    Johnson AL; Hayward KL; Patel P; Horsfall LU; Cheah AEZ; Irvine KM; Russell AW; Stuart KA; Williams S; Hartel G; Valery PC; Powell EE
    Hepatol Commun; 2022 Apr; 6(4):728-739. PubMed ID: 34783191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
    Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
    J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
    Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
    Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
    Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
    Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of patients with type 2 diabetes with non-alcoholic fatty liver disease who are at increased risk of progressing to advanced fibrosis: a cross-sectional study.
    Mettananda C; Egodage T; Dantanarayana C; Fernando R; Ranaweera L; Luke N; Ranawaka C; Kottahachchi D; Pathmeswaran A; de Silva HJ; Dassanayake AS
    BMJ Open; 2023 Jan; 13(1):e063959. PubMed ID: 36639212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease.
    Zhang X; Wong GL; Yip TC; Cheung JTK; Tse YK; Hui VW; Lin H; Lai JC; Chan HL; Kong AP; Wong VW
    Hepatology; 2022 Nov; 76(5):1409-1422. PubMed ID: 35334125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.
    Shaheen AA; Riazi K; Medellin A; Bhayana D; Kaplan GG; Jiang J; Park R; Schaufert W; Burak KW; Sargious M; Swain MG
    CMAJ Open; 2020; 8(2):E370-E376. PubMed ID: 32414883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Only one-third of referrals for fatty liver disease are on time: real-world study reveals opportunities to avoid unnecessary and delayed referrals.
    Lindvig KP; Wernberg CW; Kjaergaard M; Thorhauge KH; Alnor AB; Thiele M; Krag A
    Scand J Gastroenterol; 2022 Dec; 57(12):1478-1485. PubMed ID: 35793386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD.
    Kamada Y; Munekage K; Nakahara T; Fujii H; Sawai Y; Doi Y; Hyogo H; Sumida Y; Imai Y; Miyoshi E; Ono M;
    Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
    Vilar-Gomez E; Vuppalanchi R; Desai AP; Gawrieh S; Ghabril M; Saxena R; Cummings OW; Chalasani N
    Aliment Pharmacol Ther; 2019 Aug; 50(3):317-328. PubMed ID: 31157422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis.
    Calzadilla-Bertot L; Vilar-Gomez E; Wong VW; Romero-Gomez M; Aller-de la Fuente R; Wong GL; Castellanos M; Eslam M; Desai AP; Jeffrey GP; George J; Chalasani N; Adams LA
    Hepatology; 2021 Jun; 73(6):2238-2250. PubMed ID: 32978796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
    Wattacheril JJ; Abdelmalek MF; Lim JK; Sanyal AJ
    Gastroenterology; 2023 Oct; 165(4):1080-1088. PubMed ID: 37542503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes.
    Gracen L; Hayward KL; Aikebuse M; Russell A; O'Beirne J; McPhail S; Irvine KM; Williams S; Valery PC; Powell EE
    BMC Health Serv Res; 2022 Apr; 22(1):487. PubMed ID: 35413987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
    Boursier J; Hagström H; Ekstedt M; Moreau C; Bonacci M; Cure S; Ampuero J; Nasr P; Tallab L; Canivet CM; Kechagias S; Sánchez Y; Dincuff E; Lucena A; Roux M; Riou J; Trylesinski A; Romero-Gomez M
    J Hepatol; 2022 May; 76(5):1013-1020. PubMed ID: 35063601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.